United States Liquid Biopsy Market Research Report to 2032
ID: MRFR/HC/11817-US | 100 Pages | Author: MRFR Research Team| December 2023
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
ID: MRFR/HC/11817-US | 100 Pages | Author: MRFR Research Team| December 2023
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
US Liquid Biopsy Market Highlighted Trends & Dynamics
In 2016, the United States dominated the market with a substantial share of 85.01%, and this dominance is expected to continue with a projected Compound Annual Growth Rate (CAGR) of 29% from 2016 to 2022. Simultaneously, Canada is emerging as the fastest-growing market, poised to experience a CAGR of 25.4% during the same forecast period.Among the various components, Circulating Tumor Cells (CTCs) held the largest market share in 2016, accounting for 55.49%. This segment is anticipated to maintain its lead with a CAGR of 28.5% from 2016 to 2022. Notably, Circulating Tumor DNA (CtDNA) is the fastest-growing market within this domain, expected to exhibit a robust CAGR of 29.6%.
Cancer-related applications constituted the largest market share in 2016 at 84.75%, with an anticipated growth rate of 28.6% during the forecast period. Remarkably, the market for reproductive health is exhibiting remarkable growth, projected to achieve a CAGR of 29.3%.
In terms of sample types, blood samples dominated the market in 2016, capturing a significant share of 88.71%. The dominance of blood samples is expected to persist, with a projected CAGR of 28.6% from 2016 to 2022. Conversely, the urine sample market is emerging as the fastest-growing segment, anticipated to grow at a robust CAGR of 29.3%.
Examining market distribution channels, hospitals and laboratories held the lion's share in 2016, accounting for 45.31%. This segment is poised for continued growth with an expected CAGR of 28.9% during the forecast period. On the other hand, academic and research centers are identified as the fastest-growing market in this category, projected to experience a CAGR of 28.7%.
When focusing specifically on the breakdown between Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (CtDNA), the former accounted for a significant market share of 55.03% in 2016. Projections indicate a continued lead with an anticipated CAGR of 29.1%. Notably, Circulating Tumor DNA (CtDNA) is the fastest-growing market within this segment, expected to grow at an impressive CAGR of 30.0%.
Considering the sample types within this context, cancer-related applications continued to dominate the market in 2016, capturing a substantial share of 85.07%. This trend is expected to persist with a projected CAGR of 29.1%. Concurrently, reproductive health applications are emerging as the fastest-growing market within this category, anticipated to achieve a noteworthy CAGR of 29.9%.
In summary, the data highlights the dominance of the United States in this market, with Canada emerging as a rapidly growing player. Circulating Tumor Cells (CTCs), cancer-related applications, blood samples, and hospital/laboratory distribution channels continue to play pivotal roles, while notable growth is observed in emerging segments such as reproductive health, urine samples, and academic/research centers. These trends underscore the dynamic and evolving nature of the liquid biopsy market, with diverse applications and channels contributing to its overall growth.
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
